Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib PK in Hepatic Impairment
NCT04772612Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sitravatinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Mirati Therapeutics. Primary endpoints: Area Under the Curve from time zero to the last measurable concentration at 9 days, Time to maximum plasma concentration at 9 days and 6 more. Started Mar 2021; status: completed.
02
Drugs
sitravatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04772612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772612.